Request Demo
Last update 05 Nov 2026
Rituximab biosimilar(Hualan Genetic Engineering Co Ltd)
Last update 05 Nov 2026
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms WBP-263 |
Target |
Action inhibitors |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 27145L
The sequence is quoted from: *****
Sequence Code 83181H
The sequence is quoted from: *****
Related
5
Clinical Trials associated with Rituximab biosimilar(Hualan Genetic Engineering Co Ltd)NCT07677813
Efficacy and Safety of Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma: a Single-center, Single-arm, Prospective Study
NCT07604987
A Prospective, Multicenter, Open-Label, Single-Arm, Phase 2 Study to Evaluate the Efficacy and Safety of Rituximab, Pirtobrutinib, High-Dose Methotrexate, Dexamethasone, and Thiotepa (R-PMDT) in Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
NCT06832228
Prospective Single-center Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of Diffuse Large B-cell Lymphoma (DLBCL)
100 Clinical Results associated with Rituximab biosimilar(Hualan Genetic Engineering Co Ltd)
Login to view more data
100 Translational Medicine associated with Rituximab biosimilar(Hualan Genetic Engineering Co Ltd)
Login to view more data
100 Patents (Medical) associated with Rituximab biosimilar(Hualan Genetic Engineering Co Ltd)
Login to view more data
100 Deals associated with Rituximab biosimilar(Hualan Genetic Engineering Co Ltd)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D02994 | Rituximab biosimilar(Hualan Genetic Engineering Co Ltd) |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | NDA/BLA | China | 23 Nov 2024 | |
| CD20 positive B-Cell Lymphoma | Phase 1 | China | 19 May 2018 | |
| CD20 Positive B-Cell Non-Hodgkin Lymphoma | Phase 1 | China | 19 May 2018 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free